Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403006 | 0.79 | CYP3A4 (0.35) | CYP19A1 | |
| SCHEMBL714827 | 0.67 | MAOA (0.35) | MEN1MAPTKMT2ACYP19A1 | |
| Hydrochloric Acid SCHEMBL8638712 | 0.66 | MAOB (0.36) | CYP19A1 | |
| SCHEMBL16317354 | 0.65 | MEN1 (0.44) | MEN1MAPTKMT2ACYP19A1 | |
| SCHEMBL10610660 | 0.64 | KDM1A (0.33) | — | |
| SCHEMBL9338579 | 0.64 | KDM1A (0.33) | — | |
| SCHEMBL7169778 | 0.60 | MAPT (0.36) | MEN1MAPTKMT2ACYP19A1 | |
| SCHEMBL19213225 | 0.60 | MAPT (0.61) | MEN1MAPTKMT2ACYP19A1 | |
| SCHEMBL1128088 | 0.57 | SLC18A3 (0.50) | MEN1MAPTKMT2ACYP19A1 | |
| SCHEMBL900534 | 0.57 | SLC18A3 (0.50) | MEN1MAPTKMT2ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107445963-B | A kind of quinoxaline derivatives and its preparation method and application | 中山大学 | 2019-11-05 | — | — | CN | claimed |
| US-20210348163-A1 | The Microbiome as a Target of MicroRNAs for the Treatment of Disease | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2021-11-11 | — | — | US | disclosed |
| WO-2020041733-A1 | THE MICROBIOME AS A TARGET OF MICRORNAS FOR THE TREATMENT OF DISEASE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| US-9290464-B2 | Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-03-22 | — | — | US | disclosed |
| US-20140350062-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION | SK BIOPHARMACEUTICALS CO LTD (KR) | 2014-11-27 | — | — | US | disclosed |
| US-8841335-B2 | Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-09-23 | — | — | US | disclosed |
| EP-0669987-B1 | ADENOVIRUS VECTORS FOR THE TRANSFER OF FOREIGN GENES INTO CELLS OF THE CENTRAL NERVOUS SYSTEM, PARTICULARLY IN BRAIN | AVENTIS PHARMA SA (FR) | 2008-08-13 | — | — | EP | disclosed |
| US-6756523-B1 | Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system particularly in brain | AVENTIS PHARMA S.A. (FR) | 2004-06-29 | — | — | US | disclosed |
| US-6458529-B1 | Assays for promoter operability in central nervous system cells | AVENTIS PHARMA S.A. (FR) | 2002-10-01 | — | — | US | disclosed |
| EP-0669987-A1 | ADENOVIRUS VECTORS FOR THE TRANSFER OF FOREIGN GENES INTO CELLS OF THE CENTRAL NERVOUS SYSTEM, PARTICULARLY IN BRAIN | Aventis Pharma S.A. (FR) | 1995-09-06 | — | — | EP | disclosed |
| WO-1994008026-A1 | ADENOVIRUS VECTORS FOR THE TRANSFER OF FOREIGN GENES INTO CELLS OF THE CENTRAL NERVOUS SYSTEM, PARTICULARLY IN BRAIN | RHONE-POULENC RORER S.A. (FR) | 1994-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350062-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION | BAX, NLN, CASP3 | MEN1 4505/4885MAPT 29/4885KMT2A 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.